Drugs
General and Politics
- Bias, not conflict of interest, is the enemy
- Conflicts of interest in medical science: peer usage, peer review and ‘CoI consultancy’
- Drug Interactions with Grapefruit Juice: An Evidence-Based Overview
- Drug researchers leak secrets to Wall St.
- FDA Standards — Good Enough for Government Work?
- Financial Conflicts of Interest and the Food and Drug Administration’s Advisory Committees
- Financial Indigestion
- Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
- New systems for delivery of drugs to the brain in neurological disease
- Prescription for change
- Preventive Medicine, Properly Practiced
- The Lessons of Vioxx — Drug Safety and Sales
- When marketing and science intersect: Do patients with MS benefit?
Specific to MS
- Altered CD4 /CD8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
- Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
- How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
- Interferon beta in multiple sclerosis: how much BENEFIT?
- Natalizumab and Immune Cells
- Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
- Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
- The curious incident of disability in multiple sclerosis trials
- The elephant in the room
- The protease inhibitor, Bowman Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis
- Toward the Development of Rational Therapies in Multiple Sclerosis: What Is on the Horizon?
- A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
- Campath treatment suspended after serious risks found
- Can super-antibody drugs be tamed?
- Economic evaluation of Avonex† (interferon beta-1a) in patients following a single demyelinating event
- Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
- Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
- High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
- History of modern multiple sclerosis therapy
- Interferon beta babies
- Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment
- Lessons for clinical trials from natalizumab in MS
- Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis
- Natalizumab for Relapsing Multiple Sclerosis
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
- Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
- Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis
- Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis
- Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
- Selective Treatment of Multiple Sclerosis
- Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
- Severe anaphylactic reaction to glatiramer acetate with specific IgE
- The coming of age for antigen-specific therapy of multiple sclerosis
- The reproductive effects of beta interferon therapy in pregnancy
- Therapeutic Considerations for Disease Progression in Multiple Sclerosis
- Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
- What went wrong in the natalizumab trials?
- A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
- A prospective, open-label treatment trial to compare the effect of IFN b-1a (Avonex), IFNb-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
- A randomized, double-blind, dosecomparison study of weekly interferon B-1a in relapsing MS
- A randomized, double-blind, placebocontrolled MRI study of anti–herpes virus therapy in MS
- Additive effect of the combination of glatiramer acetate and minocycline in a model of MS
- Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines
- Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy
- Cholesterol drug counters MS symptoms in mice
- Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS
- Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS
- Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial
- Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained
- Cost of Managing an Episode of Relapse in Multiple Sclerosis in the United States
- Current Therapy of Multiple Sclerosis
- Daclizumab Zenapax inhibits early interleukin-2 receptor / signal transduction events
- Design of effective immunotherapy for human autoimmunity
- Disease modifying therapies in multiple sclerosis
- Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses
- Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine
- FTY720, a novel once-daily oral medication, shows promising results in treatment of multiple sclerosis
- Fulminant liver failure during interferon beta treatment of multiple sclerosis
- Future Immunotherapies in Multiple Sclerosis
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
- Glatiramer Acetate Therapy: The Plot Thickens
- Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy
- Growth factor treatment of demyelinating disease: at last, a leap into the light
- Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon B
- Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol
- Immunotherapies: cause for measured optimism
- Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre
- Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
- Interferons in relapsing remitting MS
- Interferons in relapsing remitting multiple sclerosis: a systematic review
- Intramuscular Interferon Beta-1A Therapy Initiated During A First Demyelinating Event In Multiple Sclerosis
- Intravenous immunoglobulin in neurological disease: a specialist review
- Is nalalizumab a breakthrough in the treatment of MS?
- Key issues in the diagnosis and treatment of multiple sclerosis
- Lack of evidence for use of glatiramer acetate in multiple sclerosis
- Liver injury associated with the B-interferons for MS
- Liver injury associated with the B-interferons for MS
- Low dose naltrexone therapy in MS
- Marijuana as a treatment for epilepsy and multiple sclerosis?
- Minocycline Reduces Gadolinium-Enhancing Magnetic Resonance Imaging Lesions in Multiple Sclerosis
- Modafinil Is Safe and Effective Treatment for MS-Related Fatigue
- Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
- Multiple Sclerosis: Update on Treatment
- Mycophenolate-Mofetil May Stabilize Patients with Progressive Multiple Sclerosis
- Nascobal
- Natalizumab and Progressive Multifocal Leukoencephalopathy
- Needed in MS Evidence, not EVIDENCE
- Neutralizing anti-IFN-B antibodies
- New directions in MS therapeutics: vehicles of hope
- Novantrone Adverse Effects
- Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis
- Oral simvastatin treatment in relapsing-remitting multiple sclerosis
- Patients at Risk
- Patterns of cannabis use among patients with multiple sclerosis
- Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis
- Preventing multiple sclerosis?
- Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn’s Disease
- Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
- Randomized, comparative study of interferon B-1a treatment regimens in MS
- Rebif Adverse Reactions
- Silencing Autoimmunity in Multiple Sclerosis, Lupus, and Rheumatoid Arthritis
- Statins as immunomodulators; Comparison with interferon-β1b in MS
- Statins for the treatment of multiple sclerosis: cautious hope
- Suppressing immunity in advancing MS
- Tackling multiple sclerosis
- The Janus face of CNS-directed autoimmune response: a therapeutic challenge
- Therapeutic potential of lovastatin in multiple sclerosis
- Therapy with glatiramer acetate for multiple sclerosis
- Transdermal Histamine in Multiple Sclerosis, Part Two: A Proposed Theoretical Basis for Its Use.
- Treatment of Multiple Sclerosis with the Pregnancy Hormone Estriol
- Treatment of severe autoimmune disease by stem-cell transplantation
- Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD
- Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
- Using stem cells in multiple sclerosis therapies
Other Diseases
- Arthritis Medicines and Cardiovascular Events—“House of Coxibs”
- Biological containment of genetically modified Lactobacillus lactis for intestinal delivery of human interleukin 10
- COX-2 Inhibitors — A Lesson in Unexpected Problems
- Immunomodulation Of Autoimmune And Inflammatory Diseases With Intravenous Immune Globulin
- New systems for delivery of drugs to the brain in neurological disease
- Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue